A study conducted by Organization for Economic
Co-operation and Development (OECD) estimates that Tc-99m diagnostic procedures
are expected to increase by 15% to 20% in mature markets such as Europe, North
America, Japan, the Republic of Korea, and Oceania between 2010 and 2030.
Radiopharmaceuticals in neurological applications such as Alzheimer’s disease,
Parkinson’s disease, and dementia are also being preferred by practitioners
besides conventional treatment. Further, upcoming radioisotopes such as Ra-223
(Alpharadin) and Ga-68 possess huge potential for clinical applications. The
scheduled shutdown of the NRU reactor in 2016 and OSIRIS in France in 2018 is,
however, a major threat for manufacturers.
“Radiopharmaceuticals” come under a special class of
pharmaceuticals, with stringent regulations on their use. The use of
radiopharmaceuticals is expanding with the improvements in production, and
increase in the number of applications. The global radiopharmaceutical market
for therapy and PET & SPECT imaging was valued at $3,213 million in 2010
and is expected to reach $4,734 million by 2015, growing at a CAGR of 8.1% from
2010 to 2015. The PET & SPECT diagnosis accounted for the largest share;
i.e. 90% of the global radiopharmaceutical market.
Radiopharmaceuticals have a high growth potential
with the increasing incidences of cancer and cardiac diseases, requiring better
imaging techniques. Targeted alpha therapy is considered to be the best form of
cancer treatment. Most of the radiopharmaceuticals are used in hospitals
accounting for 92% of their total market share.
The
therapy market is predominantly driven by its oncologic applications. Since
conventional treatment procedures of cancer, surgery and chemotherapy have
significant side effects, radioisotopes are being preferred by medical
practitioners due to minimum or no side effects. The radiopharmaceutical
therapy market is expected to grow significantly with the launch of the
much-desired Alpharadin (Ra-223) in the near future. This isotope has
tremendous potential to take up market share of beta emitters and brachytherapy.
Scope
of the Report
The
radioisotope and stable isotope markets have been segmented according to the
type of isotope, and applications. Both of these markets are broken down into
segments and sub-segments, providing exhaustive value analysis for the years
2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed
at a granular level by geography (North America, Europe, Asia, and Rest of the
World) to provide in-depth information on the global scenario.
Global
Radiopharmaceuticals Market
Diagnostic
SPECT
PET
Therapy
Beta emitters
Alpha emitters
Brachytherapy
Global Enriched Stable Isotopes Market
Radiopharmaceutical and Stable Isotope Markets, By
Geography
Buy a
Report Copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=88247
Table of Content
1
Introduction
1.1 Key Take-Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
1.5.5 Assumptions
1.1 Key Take-Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
1.5.5 Assumptions
2
Executive Summary
3
Market Overview
3.1 Definition Of Radiopharmaceuticals
3.2 Evolution 40
3.3 Market Segmentation
3.3.1 Radiopharmaceuticals
3.3.2 Stable Isotopes
3.4 Market Dynamics
3.4.1 Drivers
3.4.1.1 Increasing Incidence Of Cancer And Cardiac Ailments Boosts The Demand For Radiopharmaceuticals
3.4.1.2 Increasing Use Of Spect And Pet Scans Results In Rise Of Radiopharmaceutical Usage
3.4.1.3 Rising Awareness Of Radiopharmaceuticals To Spur Growth
3.4.1.4 Ready Availability Of Radiopharmaceuticals From Cyclotrons To Goad The Growth
3.4.2 Restraints
3.4.2.1 Shorter Half-Life Of Radiopharmaceuticals Restricts Its Usage
3.4.2.2 High Capital To Limit The Buying Of Scanners
3.4.2.3 Stringent Regulatory Guidelines And Gmp To Negatively Impact Growth
3.4.2.4 Competition From Conventional Diagnostic Procedures
3.4.3 Opportunities
3.4.3.1 Potential Radioisotopes In The Pipeline
3.4.3.2 High Demand In Emerging Countries 49
3.4.3.3 Alpha Radio Immunotherapy-Based Targeted Cancer Treatment
3.4.3.4 Alternative Diagnostic Radiopharmaceutical Solutions
3.4.3.5 Cyclotron Based Production
3.4.3.6 Neurological Applications
3.4.4 Threat
4 Global Radiopharmaceuticals Market
4.1 Introduction
4.2 Diagnostic Market
4.2.1 Opportunity Matrix
4.2.2 Single-Photon Emission Computed Tomography (Spect) Imaging
4.2.2.1 Technetium-99m (Tc-99m)
4.2.2.1.1 Tc-99m To Decide Growth Trend Of Spect Radioisotopes
4.2.2.1.2 Factors Affecting Technetium-99m Market
4.2.2.1.2.1 Technetium Can Combine With 31 Different Carrier Molecules
4.2.2.1.2.2 Lack Of Availability Of Technetium
4.2.2.2 Thallium-201 (Tl-201)
4.2.2.2.1 Tl-201 Is A Potential Substitute For Tc-99m
4.2.2.3 Gallium-67 (Ga-67)
4.2.2.3.1 Fluorine-18 Might Seize Ga-67 Market Share In The Near Future
4.2.2.4 Iodine (I-123)
4.2.2.5 Others 110
4.2.3 Pet Radiopharmaceuticals
4.2.3.1 Fluorine-18
4.2.3.1.1 Fdg
4.2.3.1.2 Florbetapir
5 Radiopharmaceuticals Market, By Application/ Indication
5.1 Introduction
5.2 Diagnostic Market
5.2.1 Spect 153
5.2.1.1 Cardiology
5.2.1.2 Lymphoma
5.2.1.3 Thyroid
5.2.1.4 Neurology
5.2.1.4.1 Alzheimer’s, Dementia, And Parkinson’s Disease Drives Growth Of The Neurology Spect Market
5.2.1.5 Others
5.2.2 Pet Application
5.2.2.1 Oncology
5.2.2.1.1 Fdg F-18 Has Become A Gold Standard For Oncology Diagnosis Using Pet Scan
5.2.2.2 Cardiology
5.2.2.3 Neurology
5.2.2.3.1 Florbetapir F-18 & Fluorodopa (F-18 Dopa) Are Potential Substitutes Of Fdg F-18
5.2.2.4 Others
5.3 Therapeutic Application
5.3.1 Thyroid 168
5.3.2 Bone Metastasis
5.3.3 Lymphoma
5.3.3.1 Novel Clinical Studies Goading Lymphoma Therapy Market
5.3.4 Endocrine Tumors
5.3.5 Others
3.1 Definition Of Radiopharmaceuticals
3.2 Evolution 40
3.3 Market Segmentation
3.3.1 Radiopharmaceuticals
3.3.2 Stable Isotopes
3.4 Market Dynamics
3.4.1 Drivers
3.4.1.1 Increasing Incidence Of Cancer And Cardiac Ailments Boosts The Demand For Radiopharmaceuticals
3.4.1.2 Increasing Use Of Spect And Pet Scans Results In Rise Of Radiopharmaceutical Usage
3.4.1.3 Rising Awareness Of Radiopharmaceuticals To Spur Growth
3.4.1.4 Ready Availability Of Radiopharmaceuticals From Cyclotrons To Goad The Growth
3.4.2 Restraints
3.4.2.1 Shorter Half-Life Of Radiopharmaceuticals Restricts Its Usage
3.4.2.2 High Capital To Limit The Buying Of Scanners
3.4.2.3 Stringent Regulatory Guidelines And Gmp To Negatively Impact Growth
3.4.2.4 Competition From Conventional Diagnostic Procedures
3.4.3 Opportunities
3.4.3.1 Potential Radioisotopes In The Pipeline
3.4.3.2 High Demand In Emerging Countries 49
3.4.3.3 Alpha Radio Immunotherapy-Based Targeted Cancer Treatment
3.4.3.4 Alternative Diagnostic Radiopharmaceutical Solutions
3.4.3.5 Cyclotron Based Production
3.4.3.6 Neurological Applications
3.4.4 Threat
4 Global Radiopharmaceuticals Market
4.1 Introduction
4.2 Diagnostic Market
4.2.1 Opportunity Matrix
4.2.2 Single-Photon Emission Computed Tomography (Spect) Imaging
4.2.2.1 Technetium-99m (Tc-99m)
4.2.2.1.1 Tc-99m To Decide Growth Trend Of Spect Radioisotopes
4.2.2.1.2 Factors Affecting Technetium-99m Market
4.2.2.1.2.1 Technetium Can Combine With 31 Different Carrier Molecules
4.2.2.1.2.2 Lack Of Availability Of Technetium
4.2.2.2 Thallium-201 (Tl-201)
4.2.2.2.1 Tl-201 Is A Potential Substitute For Tc-99m
4.2.2.3 Gallium-67 (Ga-67)
4.2.2.3.1 Fluorine-18 Might Seize Ga-67 Market Share In The Near Future
4.2.2.4 Iodine (I-123)
4.2.2.5 Others 110
4.2.3 Pet Radiopharmaceuticals
4.2.3.1 Fluorine-18
4.2.3.1.1 Fdg
4.2.3.1.2 Florbetapir
5 Radiopharmaceuticals Market, By Application/ Indication
5.1 Introduction
5.2 Diagnostic Market
5.2.1 Spect 153
5.2.1.1 Cardiology
5.2.1.2 Lymphoma
5.2.1.3 Thyroid
5.2.1.4 Neurology
5.2.1.4.1 Alzheimer’s, Dementia, And Parkinson’s Disease Drives Growth Of The Neurology Spect Market
5.2.1.5 Others
5.2.2 Pet Application
5.2.2.1 Oncology
5.2.2.1.1 Fdg F-18 Has Become A Gold Standard For Oncology Diagnosis Using Pet Scan
5.2.2.2 Cardiology
5.2.2.3 Neurology
5.2.2.3.1 Florbetapir F-18 & Fluorodopa (F-18 Dopa) Are Potential Substitutes Of Fdg F-18
5.2.2.4 Others
5.3 Therapeutic Application
5.3.1 Thyroid 168
5.3.2 Bone Metastasis
5.3.3 Lymphoma
5.3.3.1 Novel Clinical Studies Goading Lymphoma Therapy Market
5.3.4 Endocrine Tumors
5.3.5 Others
6
Enriched Stable Isotopes Market
6.1 Introduction
6.2 Market Overview
6.2.1 Asia Accounts For Largest Market Share
6.3 Market Dynamics
6.3.1 Drivers
6.3.1.1 Stable Isotopes Are Natural In Origin & Hence Safe
6.3.1.2 Proteomics & System Biology, Major Factors To Boost The Growth Of Stables
6.3.1.3 Medical Applications Propel Stable Isotopes Market Growth
6.3.2 Restraints
6.3.2.1 Harmful Effects Of Stable Isotopes Affect Market Growth
6.3.2.2 High Cost Of Stables Isotope
6.4 Enriched Stables Market, By Isotopes
6.4.1 Deuterium & O-18 Are Promising Isotopes
6.4.2 Carbon-13
6.4.3 Deuterium
6.4.4 Oxygen-18
6.4.5 Nitrogen-15
6.4.6 Other Stable Isotopes
6.5 Enriched Stables Market, By Applications
6.5.1 Diagnostic & Therapeutic
6.5.2 Research
6.5.3 Pharmaceuticals
6.5.4 Industrial Sector
6.1 Introduction
6.2 Market Overview
6.2.1 Asia Accounts For Largest Market Share
6.3 Market Dynamics
6.3.1 Drivers
6.3.1.1 Stable Isotopes Are Natural In Origin & Hence Safe
6.3.1.2 Proteomics & System Biology, Major Factors To Boost The Growth Of Stables
6.3.1.3 Medical Applications Propel Stable Isotopes Market Growth
6.3.2 Restraints
6.3.2.1 Harmful Effects Of Stable Isotopes Affect Market Growth
6.3.2.2 High Cost Of Stables Isotope
6.4 Enriched Stables Market, By Isotopes
6.4.1 Deuterium & O-18 Are Promising Isotopes
6.4.2 Carbon-13
6.4.3 Deuterium
6.4.4 Oxygen-18
6.4.5 Nitrogen-15
6.4.6 Other Stable Isotopes
6.5 Enriched Stables Market, By Applications
6.5.1 Diagnostic & Therapeutic
6.5.2 Research
6.5.3 Pharmaceuticals
6.5.4 Industrial Sector
7
Geographic Analysis
7.1 Introduction
7.2 Diagnostic Market
7.2.1 North America
7.2.1.1 Increasing Adoption Of Alternative Production Technologies To Make Up For The Shortage Of Mo-99
7.2.2 Europe
7.2.2.1 Stringent Regulations Hindering Market Growth
7.2.3 Asia
7.2.3.1 Asia Promises The Highest Cagr In The Forecast Period
7.2.4 Rest Of The World (Row)
7.3 Therapy Market
7.3.1 North America
7.3.1.1 Nuclear Medicine Research Drives The Beta Emitters Market
7.3.2 Europe
7.3.3 Asia
7.3.4 Rest Of The World (Row)
7.4 Enriched Stable Isotopes Market
7.4.1 Asia
7.4.2 North America
7.4.3 Europe
7.4.4 Rest Of The World (Row)
7.1 Introduction
7.2 Diagnostic Market
7.2.1 North America
7.2.1.1 Increasing Adoption Of Alternative Production Technologies To Make Up For The Shortage Of Mo-99
7.2.2 Europe
7.2.2.1 Stringent Regulations Hindering Market Growth
7.2.3 Asia
7.2.3.1 Asia Promises The Highest Cagr In The Forecast Period
7.2.4 Rest Of The World (Row)
7.3 Therapy Market
7.3.1 North America
7.3.1.1 Nuclear Medicine Research Drives The Beta Emitters Market
7.3.2 Europe
7.3.3 Asia
7.3.4 Rest Of The World (Row)
7.4 Enriched Stable Isotopes Market
7.4.1 Asia
7.4.2 North America
7.4.3 Europe
7.4.4 Rest Of The World (Row)
8
Competitive Landscape
8.1 Introduction
8.2 Mergers & Acquisitions
8.3 Agreements, Partnerships, Collaborations & Joint Ventures
8.4 Products Launch
8.5 Expansions
8.6 Other Developments
8.7 Approvals
8.1 Introduction
8.2 Mergers & Acquisitions
8.3 Agreements, Partnerships, Collaborations & Joint Ventures
8.4 Products Launch
8.5 Expansions
8.6 Other Developments
8.7 Approvals
9
Company Profiles
(Overview, Financials, Products & Services, Strategy, & Developments)*
9.1 Bracco Imaging S.P.A.
9.2 Cambridge Isotope Laboratories, Inc.
9.3 Cardinal Health, Inc.
9.4 Covidien, Plc
9.5 Eczacibasi-Monrol
9.6 Fujifilm Holdings Corporation
9.7 Ge Healthcare (Subsidiary Of General Electric Company)
9.8 Iba Group 286
9.9 Isotec, Inc. (Sigma-Aldrich)
9.10 Lantheus Medical Imaging, Inc.
9.11 Nordion, Inc.
9.12 Ntp Radioisotopes (Pty), Ltd.
9.13 Petnet Solutions, Inc. (A Subsidiary Of Siemens Medical Solutions Usa, Inc.)
9.14 Taiyo Nippon Sanso Corporation
9.15 Urenco Limited
9.16 Rotem Industries, Ltd., Inc.
9.17 Australian Nuclear Association And Technology Organization (Ansto)
9.18 Board Of Radiation And Isotope Technology (Brit)
9.19 Institute Of Atomic Energy Polatom Radioisotope Centre
9.20 Institute Of Isotopes Co., Ltd.
9.21 Institute Of Radioelement (Ire)
(Overview, Financials, Products & Services, Strategy, & Developments)*
9.1 Bracco Imaging S.P.A.
9.2 Cambridge Isotope Laboratories, Inc.
9.3 Cardinal Health, Inc.
9.4 Covidien, Plc
9.5 Eczacibasi-Monrol
9.6 Fujifilm Holdings Corporation
9.7 Ge Healthcare (Subsidiary Of General Electric Company)
9.8 Iba Group 286
9.9 Isotec, Inc. (Sigma-Aldrich)
9.10 Lantheus Medical Imaging, Inc.
9.11 Nordion, Inc.
9.12 Ntp Radioisotopes (Pty), Ltd.
9.13 Petnet Solutions, Inc. (A Subsidiary Of Siemens Medical Solutions Usa, Inc.)
9.14 Taiyo Nippon Sanso Corporation
9.15 Urenco Limited
9.16 Rotem Industries, Ltd., Inc.
9.17 Australian Nuclear Association And Technology Organization (Ansto)
9.18 Board Of Radiation And Isotope Technology (Brit)
9.19 Institute Of Atomic Energy Polatom Radioisotope Centre
9.20 Institute Of Isotopes Co., Ltd.
9.21 Institute Of Radioelement (Ire)
For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441
No comments:
Post a Comment
Note: only a member of this blog may post a comment.